99 related articles for article (PubMed ID: 12134168)
41. [Retard forms of insulin by matrix inclusion or complex formation].
Losse G; Müller F; Raddatz H; Naumann W; Kossowicz J
Pharmazie; 1988 May; 43(5):355-7. PubMed ID: 3051057
[No Abstract] [Full Text] [Related]
42. [Comparison of hypoglycemic activity of crystalline and recrystallized insulin preparations and their fractions].
Chojecka H; Deptuła S; Robel A
Acta Pol Pharm; 1976; 33(6):747-51. PubMed ID: 1015332
[No Abstract] [Full Text] [Related]
43. [On new insulin preparations with prolonged action].
Preobrazhenskiĭ AP
Klin Med (Mosk); 1966 May; 44(5):3-7. PubMed ID: 5989394
[No Abstract] [Full Text] [Related]
44. Preparations and properties of crystalline porcine and bovine [Trp]B1 insulins.
Lei KJ; Wang ZZ; Dong B; Ru BG; Zhu SQ
Sci Sin; 1980 Nov; 23(11):1443-52. PubMed ID: 7015497
[TBL] [Abstract][Full Text] [Related]
45. Assessing whether controlled release products with differing in vitro dissolution rates have the same in vivo-in vitro relationship.
Cao G; Locke C
Adv Exp Med Biol; 1997; 423():173-80. PubMed ID: 9269493
[No Abstract] [Full Text] [Related]
46. Understanding insulin: the old and new.
Wilson HK; Field JB
Adv Intern Med; 1984; 29():357-84. PubMed ID: 6369929
[No Abstract] [Full Text] [Related]
47. Chemical modifications of insulin: Finding a compromise between stability and pharmaceutical performance.
Akbarian M; Ghasemi Y; Uversky VN; Yousefi R
Int J Pharm; 2018 Aug; 547(1-2):450-468. PubMed ID: 29890260
[TBL] [Abstract][Full Text] [Related]
48. Insulin pharmacology.
Skyler JS
Med Clin North Am; 1988 Nov; 72(6):1337-54. PubMed ID: 3054356
[TBL] [Abstract][Full Text] [Related]
49. Controlled release--third annual SMi conference. 9-10 February 2004, London, UK.
Phillips T
IDrugs; 2004 Mar; 7(3):235-7. PubMed ID: 15017465
[No Abstract] [Full Text] [Related]
50. [Specific pharmacodynamics of depot insulin preparations].
Mehnert H
Dtsch Med Wochenschr; 1972 Oct; 97(42):1618. PubMed ID: 5077554
[No Abstract] [Full Text] [Related]
51. [Crystalline form of progesterone in silicone elastomers].
Bernabei MT; Gamberini G; Ferioli V; Cameroni R
Boll Chim Farm; 1982 Jul; 121(7):347-53. PubMed ID: 7150443
[No Abstract] [Full Text] [Related]
52. [Insulin: from structural determination to chemical synthesis].
Zahn H
MMW Munch Med Wochenschr; 1983 May; Suppl 1():S3-13. PubMed ID: 6408429
[No Abstract] [Full Text] [Related]
53. [The insulin pill].
Rehfeld JF
Ugeskr Laeger; 1999 Jul; 161(30):4299. PubMed ID: 10439694
[No Abstract] [Full Text] [Related]
54. [Biological activity of fully synthetic insulin preparations].
Pohlmeyer U; Otto H
Klin Wochenschr; 1965 Aug; 43(16):853-4. PubMed ID: 5862688
[No Abstract] [Full Text] [Related]
55. Human insulin.
Home P
Br Med J (Clin Res Ed); 1986 Mar; 292(6520):625-6. PubMed ID: 3081201
[No Abstract] [Full Text] [Related]
56. Preparation and characterization of a fully iodinated insulin derivative.
GRUEN L; LASKOWSKI M; SCHERAGA HA
J Biol Chem; 1959 Aug; 234(8):2050-3. PubMed ID: 13673012
[No Abstract] [Full Text] [Related]
57. A physiologically active guanidinated derivative of insulin.
EVANS RL; SAROFF HA
J Biol Chem; 1957 Sep; 228(1):295-304. PubMed ID: 13475318
[No Abstract] [Full Text] [Related]
58. Cocrystal systems of pharmaceutical interest: 2007-2008.
Brittain HG
Profiles Drug Subst Excip Relat Methodol; 2010; 35():373-90. PubMed ID: 22469227
[No Abstract] [Full Text] [Related]
59. Spectroscopic insights into multi-phase protein crystallization in complex lysate using Raman spectroscopy and a particle-free bypass.
Wegner CH; Eming SM; Walla B; Bischoff D; Weuster-Botz D; Hubbuch J
Front Bioeng Biotechnol; 2024; 12():1397465. PubMed ID: 38812919
[TBL] [Abstract][Full Text] [Related]
60. Reversible crystallization of argatroban after subcutaneous application in pigs.
Lopez M; Nowak G
Thrombosis; 2012; 2012():560513. PubMed ID: 22988498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
